Proxalutamide (GT0918) Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration - an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial

Proxalutamide study #5 of 7 All Outcomes

7/2 Late treatment study

Zimerman et al., medRxiv, doi:10.1101/2021.06.28.21259661 (Preprint)
Proxalutamide (GT0918) Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration - an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial

Source PDF Share Tweet

Analysis of treatment duration in the Proxa-Rescue AndroCoV trial showing significantly higher mortality among patients that interrupted treatment with proxalutamide. NCT04728802.

Zimerman et al., 7/2/2021, preprint, 17 authors.

All 7 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit